SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

SAN

73.05

+0.48%↑

ARGX

691.2

+0.82%↑

SHL.DE

34.15

+1.1%↑

FRE

38.92

+1.91%↑

PHIA

22.03

+1.06%↑

Home・Akcijų sąrašas・Fagron

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

23.9 0.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.65

Max

23.9

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-99K 45M
Pardavimai	-98K 476M
P/E Sektoriaus vid.	19.395 51.415
Dividendų pajamingumas	1.67
Pelno marža	9.55
Darbuotojai	4,193
EBITDA	11M 98M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+20.59% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.67% 2.34%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	134M 1.8B
Ankstesnė atidarymo kaina	23.69
Ankstesnė uždarymo kaina	23.9

Naujienos nuotaikos

By Acuity

100%

329 / 346 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 22:54; UTC

Uždarbis

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026-05-13 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-13 23:51; UTC

Rinkos pokalbiai

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-13 23:17; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-13 23:16; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026-05-13 23:15; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026-05-13 23:14; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026-05-13 23:02; UTC

Rinkos pokalbiai

Uždarbis

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026-05-13 22:59; UTC

Rinkos pokalbiai

Uždarbis

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026-05-13 22:24; UTC

Uždarbis

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Revenue Growth 47%>XRO.AU

2026-05-13 22:22; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026-05-13 22:18; UTC

Uždarbis

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026-05-13 22:16; UTC

Uždarbis

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026-05-13 22:13; UTC

Uždarbis

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026-05-13 22:12; UTC

Uždarbis

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026-05-13 22:09; UTC

Uždarbis

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026-05-13 22:00; UTC

Uždarbis

Cisco to Shed Jobs for All-In AI Push -- Update

2026-05-13 21:11; UTC

Uždarbis

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR 20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Fagron akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

329 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.